In­hi­brx shares rise on PhI tri­al re­sults; Bragli­a's Helsinn en­ters part­ner­ship with Fo­s­un

Cal­i­for­nia biotech In­hi­brx re­leased in­ter­im re­sults to­day from a Phase I tri­al look­ing at a re­com­bi­nant fu­sion pro­tein pro­gram, IN­BRX-101. The study looked at pa­tients with al­pha-1 an­tit­rypsin de­fi­cien­cy, or AATD.

The study re­vealed in­ter­im phar­ma­co­ki­net­ic da­ta from 21 pa­tients with AATD, all with the ZZ mu­ta­tion of the SER­PINA1 gene, and in­ter­im safe­ty da­ta are from 24 pa­tients with AATD. There were no drug-re­lat­ed se­vere or se­ri­ous ad­verse events at dos­es up to and in­clud­ing 120 mg/kg sin­gle dose, and 80mg/kg mul­ti-dose, ac­cord­ing to a com­pa­ny re­lease. Ad­verse events were pre­dom­i­nant­ly mild with a few mod­er­ate events.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER